Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.
Clemow DB. et al, (2025), Journal of patient-reported outcomes, 9
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Fiorino G. et al, (2025), Journal of Crohn's & colitis, 19
Impact of Mirikizumab Treatment on Fatigue in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
Regueiro M. et al, (2025), Journal of Crohn's & colitis
Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis.
Panaccione R. et al, (2025), Crohn's & colitis 360, 7
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.
Lee SD. et al, (2025), The American journal of gastroenterology
Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres.
Young D. et al, (2025), Drugs in context, 14
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
Thomas T. et al, (2024), Nature Immunology, 25, 2152 - 2165
Value of Engagement in Digital Health Technology Research: Evidence Across 6 Unique Cohort Studies.
Goodday SM. et al, (2024), Journal of medical Internet research, 26
Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
Wong S-Y. et al, (2023), Inflammatory bowel diseases, 29, 1693 - 1705
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases (IBD): Real World Results from the International Organization for the study of IBD.
Vieujean S. et al, (2023), Journal of Crohn's & colitis
Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs
Matini L. et al, (2023), Journal of Crohn's and Colitis
An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis.
Mortlock S. et al, (2023), Journal of Crohn's & colitis, 17, 277 - 288
Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
Adams A. et al, (2023), Gut, 72, 433 - 442
Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy.
Chauhan D. et al, (2023), Frontline gastroenterology, 14, 432 - 434
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
Wong D. et al, (2022), Journal of Crohn's and Colitis, 16, 1874 - 1881
Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Liu Z. et al, (2022), Journal of Crohn's & colitis, 16, 1835 - 1844
Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care.
Barnes A. et al, (2022), Intestinal research, 20, 506 - 508
A MULTICENTRE EXPERIENCE OF HOME FAECAL CALPROTECTIN (CALPROSMARTTM) TESTING DURING THE COVID-19 PANDEMIC
Al-Hillawi L. et al, (2022), GUT, 71, A37 - A37
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study.
Honap S. et al, (2022), Frontline gastroenterology, 13, 517 - 523
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
McGregor CG. et al, (2021), Gut, 70, 2398 - 2400